Brokers Issue Forecasts for Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Kura Oncology in a research report issued on Wednesday, March 19th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($2.21) for the year, up from their prior estimate of ($2.94). Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analysts’ expectations of $57.96 million.

A number of other brokerages have also issued reports on KURA. StockNews.com lowered Kura Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday. UBS Group lowered their target price on shares of Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. JMP Securities reiterated a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research report on Thursday, February 6th. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Trading Down 0.1 %

KURA stock opened at $7.84 on Friday. Kura Oncology has a 12-month low of $6.79 and a 12-month high of $23.48. The business’s 50-day moving average is $7.82 and its 200 day moving average is $12.49. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $633.12 million, a price-to-earnings ratio of -3.32 and a beta of 0.85.

Insider Activity

In related news, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock valued at $92,307 in the last 90 days. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the stock. RA Capital Management L.P. acquired a new stake in Kura Oncology in the 4th quarter valued at approximately $38,769,000. Millennium Management LLC grew its stake in shares of Kura Oncology by 180.1% in the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock valued at $20,618,000 after buying an additional 1,521,954 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Kura Oncology in the fourth quarter valued at $8,518,000. Marshall Wace LLP purchased a new stake in shares of Kura Oncology in the 4th quarter valued at $8,265,000. Finally, D. E. Shaw & Co. Inc. lifted its stake in Kura Oncology by 172.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company’s stock worth $10,027,000 after acquiring an additional 727,987 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.